In an era where drug-resistant bacteria continue to challenge the efficacy of traditional medicine, a new class of antibiotics is emerging as a beacon of hope.Kinvard Bio, a pioneering biotechnological company founded in the heart of Harvard University, is at the forefront of antibiotic discovery, targeting the critical issue of antimicrobial resistance.